RA'ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW), a developer of medical technology, has announced a significant technological milestone for its VORTX™ blood oxygenation device. The device successfully met 100% of blood oxygenation requirements while maintaining a zero pressure gradient, a factor linked to reduced blood damage, during regulatory guideline testing.
The VORTX™, which is part of the INSPIRA™ ART (Gen 2) device, aims to provide a safer and more effective alternative to traditional fiber membrane-based oxygenators, which are known to cause complications due to high mechanical shear stress (HMSS). This stress can lead to hemolysis, bleeding, inflammation, and blood clots.
Dr. Daniella Yeheskely-Hayon, Chief Technology Officer of Inspira Technologies, highlighted the significance of this breakthrough, noting the potential for their proprietary technology to promote a less damaging blood flow regime and eliminate the need for current membrane fibers-based devices.
The company's experiments demonstrated the VORTX™'s ability to perform oxygenation, carbon dioxide removal, and maintain pressure levels during use with blood. The design suggests that even at higher flow rates, the pressure across the device could remain negligible to zero.
Inspira Technologies envisions that their technology will encourage a shift from fiber membrane-based devices to those offering efficient gas exchange without long-term complications. The transition away from fiber membrane materials is also expected to reduce manufacturing costs and lessen global reliance on a single raw material supplier.
This news is based on a press release statement from Inspira Technologies.
InvestingPro Insights
In light of Inspira Technologies' announcement regarding their VORTX™ blood oxygenation device, investors may be curious about the company's financial health and market performance. According to InvestingPro data, Inspira Technologies holds a market capitalization of 25.4 million USD. Despite the potential of their medical technology, the company has not been profitable over the last twelve months, as evidenced by a negative P/E ratio of -2.23.
Investors should note that Inspira Technologies has been experiencing strong stock price movements, with a significant return of 111.35% over the last month and 104.3% over the last three months. This volatility is something to consider when evaluating the investment potential of the company. Additionally, InvestingPro Tips indicate that while Inspira Technologies holds more cash than debt, it is quickly burning through cash and suffers from weak gross profit margins.
For those considering a deeper dive into Inspira Technologies' financials and stock performance, there are additional InvestingPro Tips available. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes access to these valuable insights. Currently, there are 9 more tips listed on InvestingPro for Inspira Technologies that could help investors make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.